Non-vitamin K dependent oral anticoagulants (NOAC) are now widely used in patients with nonvalvular atrial fibrillation (NVAF) for stroke prevention and in patients with venous thromboembolism (VTE) for the treatment and secondary prevention of the disease. Among NOAC, edoxaban demonstrated noninferiority to warfarin for stroke prevention in NVAF and for VTE treatment, with superior safety. EMIT-AF/VTE (Edoxaban Management in Diagnostic and Therapeutic Procedures) (NCT02950168) is a multicenter, prospective, and noninterventional registry study designed to collect detailed information on the periprocedural management of patients with NVAF and VTE receiving edoxaban. The primary objective of EMIT-AF/VTE is to document the periprocedural management of patients receiving edoxaban and to collect data on safety and other outcomes in these patients. The primary safety outcome is the rate of major bleeding. Other assessments include the evaluation of efficacy outcomes, periprocedural dosing, and timing of edoxaban. The observation period will start 5 days prior to the procedure and end 30 days post-procedure. EMIT-AF/VTE will aim to prospectively enroll up to approximately 1400 procedures from Europe. Enrollment commenced in December 2016 and will be completed in July 2018. As of July 2018, before database lock and with several procedure forms still temporarily inserted, a preliminary number of 1204 patients have been enrolled, who underwent a total of 1453 procedures. The prospective EMIT-AF/VTE registry program will expand the knowledge of periprocedural management of patients with NVAF and VTE receiving edoxaban in clinical practice.
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| INTRODUCTION
Non-vitamin K dependent oral anticoagulants (NOAC) are increasingly used in patients with nonvalvular atrial fibrillation (NVAF) for stroke prevention and in patients with venous thromboembolism (VTE) for the treatment and secondary prevention of the disease. NOAC administration is a long-term treatment for the majority of these patients. 1, 2 Annually, at least 10% of patients receiving anticoagulation therapy undergo diagnostic and therapeutic procedures. 3 The bleeding risks of these procedures vary from minimal (eg, colonoscopy) and minor (eg, phacoemulsification) to high (eg, major surgery). Given the wide range in bleeding risk and the plethora of therapeutic options for anticoagulation, including vitamin K antagonists (VKAs), heparin, and NOAC, different treatment recommendations will inevitably emerge. 1, 4 Bridging with low-molecular-weight heparin (LMWH) could benefit patients receiving VKAs due to the late onset of action of VKAs and its long-lasting anticoagulation effect following discontinuation; however, in patients receiving NOAC, bridging with LMWH may be associated with higher risks of bleeding. 4 The short half-lives of NOAC of 5 to 15 hours and their rapid onset of action with maximum plasma concentrations achieved in 1 to 4 hours after administration may allow for brief periods of treatment interruption without the need for heparin bridging. The Steering Committee, in addition to supporting the Executive Committee in the overall oversight of the study, assures the study's implementation to optimize the quality of the data and study integrity.
The steering Committee will make the decision to submit the paper for publication, and that the funding source has no role in this deci- The primary objective of this registry is to document the periprocedural management of patients receiving edoxaban and to collect data on safety and other outcomes in these patients. The primary safety outcome is the rate of major bleeding from 5 days prior to the procedure to 30 days postprocedure using the International Society of Thrombosis and Hemostasis (ISTH) definition 14, 15 (Table S1 ). Other safety outcomes include the rates of CRNM bleeding, minor bleeding, all bleeding, and death from any cause. CRNM bleeding events are defined as overt bleeding that requires medical attention and that does not fulfill the criteria for a major bleeding event. A complete list of all procedures divided by European Heart Rhythm Association bleeding risk are listed in Table S2 . Table S3 .
The observation period of the study will start 5 days prior to the procedure and end 30 days postprocedure in all patients. The study design is shown in Figure 1 . Since this is a noninterventional study, only data on routine clinical practice will be documented. In order to enhance the quality of data by capturing important details of the diagnostic and therapeutic procedures, and medication adherence/compliance, patients may will receive a memory aid (a booklet to complete) at enrollment into the study. This booklet is the basis of data capturing during the follow-up phone call at 30 days.
| Patient population and eligibility
EMIT is planned to include approximately 1400 procedures from Europe (Belgium, Germany, Italy, the Netherlands, Spain, Portugal, and the UK). Enrollment and data collection commenced in December 2016 and will complete in July 2018. As of July 2018, before database lock and with several procedure forms still temporarily inserted, a preliminary number of 1204 patients were enrolled, who underwent a total of 1453 procedures.
Patients ≥18 years of age will be eligible to enroll if they have AF or VTE treated with edoxaban, according to local label, prior to enrollment into this registry, with a scheduled or unscheduled diagnostic/ therapeutic procedure (see Table S2 for full listing of procedures), and if they are not enrolled in any other interventional study. All safety measures that occur between enrollment and final follow-up will be recorded. These include major, CRNM, minor, and all bleeding, and death from any cause. Similarly, all efficacy measureswhich include acute coronary syndrome, nonhemorrhagic stroke, TIA, SEE, DVT, PE, and CV mortality-will be recorded.
| Data management
All clinical data will be documented using the Medidata Rave Electronic Data Capture system (New York, New York). In the start-up phase, a data management plan has been created that describes all functions, processes, and specifications for data collection, cleaning, and validation. Automated plausibility checks at data entry are performed to obtain immediate feedback if data are missing, out of range, illogical, or potentially erroneous allowing for correction FIGURE 1 Design of the EMIT registry program. This flow chart will be repeated for any further procedures for a patient or confirmation by the site. Concurrent manual data review will also be performed based on parameters defined in the data management plan.
| Sample size estimation
EMIT intends to document 1415 procedures within Europe, acknowledging regional therapeutic practices. This assumption is based on recent published data from the Dresden NOAC registry investigating the periprocedural management of NOACs in daily care. 5 In this registry, 2179 patients were enrolled. A total of 595 (27.3%) patients underwent 863 surgical or therapeutic procedures. Ten major bleeding complications (1.2%) occurred during the follow-up period of 30 AE5 days. Another cohort study reported 10 major bleedings (1.8%) in 541 procedures occurring during the 30-day follow-up. 7 The sample size estimation for EMIT is based on the rate of major bleeding at 30 days and is assumed to be 1.5% based on the above studies. To estimate the 95% confidence interval (CI) with an acceptable precision range, the width of confidence limit should be half of the above expected rate of major bleeding, less than 0.75%.
Therefore, the Executive Committee set the distance from proportion to limit as 0.65%, less than the acceptable 0.75%, with a calculated sample size of 1344 procedures. Assuming a 5% dropout rate, 1415 procedures should allow for a reasonable estimation of the event rate.
It should be noted, that the 1.5% bleeding rate is based on NOAC-treated patients who had an elective not urgent surgery/ procedure. In urgent surgery the incidence of bleeding may be higher.
| Statistical analysis
Binary, categorical, and ordinal parameters will be summarized by means of absolute and percentage numbers. Numerical data will be described by standard statistics. The statistical analyses will be performed using SAS version 9.3 or higher (SAS Institute, Cary, North Carolina). Two-sided 95% CI and/or P values will be presented for important parameters. Additional selection criteria for patients (eg, subgroup analyses) will be considered for variables of interest, if arising as useful during the statistical analyses. The purpose of all analyses will be descriptive and exploratory.
| Quality control and ethics
Data quality checks will be performed on a regular basis to ensure that the patient rights are protected, the reported data are accurate and complete, and the conduct of the study is in compliance with the observational plan and regulatory requirements. The study will be conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice, Good Pharmacovigilance Practices, and the ethical principles specified in the Declaration of Helsinki. Informed consent will be obtained from the participants prior to enrollment.
All study sites will be remotely monitored and there will also be on-site monitoring in 17% of randomly selected study sites; the monitor will verify 100% of informed consent documentation and perform source data verification against the patient's medical records in randomly selected patients (three per site). Particular attention will be paid to the completeness and correctness of safety data during monitoring activities.
| DISCUSSION
Annually, approximately 10% of patients receiving anticoagulation therapy undergo diagnostic or therapeutic procedures. 3 bridged and nonbridged patients was previously reported. 18 Subanalyses of the large phase 3 studies of NOAC have provided insight into the topic [8] [9] [10] [11] (Table 1) ; however, extrapolation to medical practice is limited. Recognizing the differences between clinical study protocoldriven and real world daily medical practice-driven oral anticoagulant treatment decisions, researchers have initiated a series of prospective registries and controlled studies ( Table 2) .
To fill the data gap on periprocedural management of patients on edoxaban, the ongoing EMIT study was devised. It is the first interna- were arterial thromboembolism and major bleeding as defined by the ISTH criteria 14 (see Table S1 ). The limitations of this study encompass the need for a full therapeutic dose of dalteparin starting early after surgery, the overlap with the restart of warfarin, and the small percentage of patients undergoing high-risk procedures. Moreover, the definition of high-risk surgeries per se is questionable since these included procedures that usually do not have a high risk of bleeding (eg, pacemaker or internal defibrillator insertion, biopsy of kidney or prostate, and any other procedure lasting ≥1 hour).
In patients with AF receiving edoxaban, periprocedural adverse outcomes are available from a prespecified post hoc subanalysis from the ENGAGE-AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) study. 12 In this analysis, "noninterruption" was defined as either continuation or discontinuation of edoxaban for ≤3 days presurgery, whereas "interruption" was defined as stopping edoxaban 4 to 10 days presurgery. 11 Although the difference in outcomes when interrupting edoxaban for 1, 2, or 3 days is not reported in the study, the half-life of edoxaban (10-14 hours) suggests that an interval of 24 to 48 hours might be a reasonable approach to reduce plasma concentrations to safe levels allowing for surgical procedures at low risk of bleeding. Another unknown in the study is the time from the end of procedure until the administration of the first dose. It is also unknown if patients were bridged with LMWH during the period of anticoagulation interruption and if bridging could have influenced the adverse outcomes. Therefore, the available data do not provide specific management guidance for patients on edoxaban undergoing diagnostic or therapeutic 
| CONCLUSIONS
Regarding the periprocedural management of anticoagulation therapy, in particular with oral agents, in patients with AF or VTE, the relevant guidelines (eg, American College of Cardiology, the American Heart Association, and the European Heart Rhythm Association) are inconsistent. 4, 19, 22 EMIT will provide data on the use of the direct factor Xa inhibitor edoxaban in real world clinical practice to support further alignment of the above guidelines. and Cathy ZL Chen for her significant contribution to the preparation of the manuscript.
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